reference_id,source_order,author_or_organization,publication_year,citation_text,doi,doi_url,source_url,source_type,subject_tags,chapter_numbers,chapter_titles
ULON-REF-0001,1,Adunsky,2011,"Adunsky A, Chandler J, Heyden N, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr 2011;53:183-189.",,,,Randomized clinical trial,Growth Hormone Axis; MK-677,15,MK-677 (Ibutamoren)
ULON-REF-0002,2,Al-Dulaimi,2025,"Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26:178. doi:10.1007/s10522-025-10315-x.",10.1007/s10522-025-10315-x,https://doi.org/10.1007/s10522-025-10315-x,https://doi.org/10.1007/s10522-025-10315-x,Journal article or scholarly source,Epitalon; Peptides,20,Epitalon
ULON-REF-0003,3,Araj,2025,"Araj M, Brzezik M, Mądra-Gackowska K, Szeleszczuk Ł. Epitalon — 25 years of research. Int J Mol Sci 2025.",,,https://www.mdpi.com/1422-0067/26/6/2691,Journal article or scholarly source,Epitalon; Peptides,20,Epitalon
ULON-REF-0004,4,Aronne,2025,"Aronne LJ, Horn DB, le Roux CW, et al; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025;393:26-36.",,,,Journal article or scholarly source,GLP-1 Therapies; GLP-1 and GIP Therapies; Semaglutide; Tirzepatide,6; 7,"Semaglutide: More Than a Weight-Loss Drug; Tirzepatide: Two Signals, One Powerful Therapy"
ULON-REF-0005,5,Badenhorst,2016,"Badenhorst T, Svirskis D, Wu Z. Pharmaceutical strategies for the topical dermal delivery of peptides/proteins for cosmetic and therapeutic applications. Austin J Pharmacol Ther 2016;4:1083.",,,,Journal article or scholarly source,GHK-Cu; Skin and Aesthetic Medicine,19; 40,GHK-Cu; Skin and Aesthetic Interventions
ULON-REF-0006,6,Barzilai,2016,"Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016;23:1060-1065. doi:10.1016/j.cmet.2016.05.011.",10.1016/j.cmet.2016.05.011,https://doi.org/10.1016/j.cmet.2016.05.011,https://doi.org/10.1016/j.cmet.2016.05.011,Journal article or scholarly source,,26; 48,Rapamycin and the mTOR Pathway; The Future of Comprehensive Practice
ULON-REF-0007,7,Bauer,2013,"Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc 2013;14:542-559.",,,,Journal article or scholarly source,Lifestyle Foundations; Nutrition,36,Nutrition
ULON-REF-0008,8,Beck,2014,"Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014;29:1527-1534.",,,,Randomized clinical trial,Growth Hormone Axis; Ipamorelin,13,Ipamorelin
ULON-REF-0009,9,Bell,2019,"Bell CG, Lowe R, Adams PD, et al. DNA methylation aging clocks: challenges and recommendations. Genome Biol 2019;20:249.",,,,Journal article or scholarly source,Biological Aging; Lifespan Framework,47,The Lifespan Framework — Adaptation Across Demographics
ULON-REF-0010,10,Belsky,2022,"Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife 2022;11:e73420.",,,,Journal article or scholarly source,Biological Aging; Lifespan Framework,47; 48,The Lifespan Framework — Adaptation Across Demographics; The Future of Comprehensive Practice
ULON-REF-0011,11,Ben-Shlomo,2020,"Ben-Shlomo A, Deng N, Ding E, et al. DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas. J Clin Invest 2020;130:5738-5755.",,,,Journal article or scholarly source,,14,CJC-1295
ULON-REF-0012,12,Berry,2020,"Berry SE, Valdes AM, Drew DA, et al. Human postprandial responses to food and potential for precision nutrition. Nat Med 2020;26:964-973.",,,,Journal article or scholarly source,Lifestyle Foundations; Nutrition,36; 48,Nutrition; The Future of Comprehensive Practice
ULON-REF-0013,13,Bjedov,2010,"Bjedov I, Toivonen JM, Kerr F, et al. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab 2010;11:35-46.",,,,Journal article or scholarly source,Molecular Longevity; Rapamycin and mTOR,26; 48,Rapamycin and the mTOR Pathway; The Future of Comprehensive Practice
ULON-REF-0014,14,Bliss,1982,Bliss M. The Discovery of Insulin. University of Chicago Press; 1982.,,,,Book,Peptide Foundations,1; 2,"The Body Speaks in Signals; Not a Steroid, Not a Supplement, Not Snake Oil"
ULON-REF-0015,15,Bock-Marquette,2004,"Bock-Marquette I, Saxena A, White MD, et al. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004;432:466-472.",,,,Journal article or scholarly source,Peptides; TB-500 and Thymosin Beta-4,18,TB-500 (Thymosin Beta-4)
ULON-REF-0016,16,Bornstein,2016,"Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016;101:364-389.",,,,Guideline or position statement,DHEA and Adrenal Steroids; Hormone Optimization,32,DHEA and Adrenal Steroids
ULON-REF-0017,17,Brakedal,2022,"Brakedal B, Dölle C, Riemer F, et al. The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. Cell Metab 2022;34:396-407.e6.",,,,Randomized clinical trial,Molecular Longevity; NAD+,25,NAD⁺ and Its Precursors
ULON-REF-0018,18,Brea-Gómez,2025,"Brea-Gómez B, Pérez-Llanes R, Ortega-Donaire L, et al. Effectiveness of pelvic floor muscle training with biofeedback in patients undergoing radical prostatectomy: systematic review and meta-analysis. Eur Urol Focus 2025; published online ahead of print.",,,https://pubmed.ncbi.nlm.nih.gov/40318944/,Meta-analysis,Bladder and Pelvic Floor Health; Urologic Health,41,"Bladder, Pelvic Floor, and Continence Rehabilitation"
ULON-REF-0019,19,Bretthauer,2022,"Bretthauer M, Løberg M, Wieszczy P, et al. Effect of colonoscopy screening on risks of colorectal cancer and related death. N Engl J Med 2022;387:1547-1556. (NordICC trial.)",,,,Journal article or scholarly source,Early Detection and Intervention,44,Early Intervention and the Minimally Invasive Framework
ULON-REF-0020,20,Budoff,2018,"Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of Atherosclerosis (MESA). Eur Heart J. 2018;39:2401-2408. doi:10.1093/eurheartj/ehy217.",10.1093/eurheartj/ehy217,https://doi.org/10.1093/eurheartj/ehy217,https://doi.org/10.1093/eurheartj/ehy217,Journal article or scholarly source,Early Detection and Intervention,44; 46,Early Intervention and the Minimally Invasive Framework; Maintenance — The Long-Term Framework
ULON-REF-0021,21,Cohen,2019,"Cohen PA, Bass S. Injecting safety into supplements — modernizing the dietary supplement law. N Engl J Med 2019;381:2387-2389.",,,,Journal article or scholarly source,Regulatory and Compounding Policy,3; 23; 35; 42,The Regulatory Landscape — August 2026 Evidence Review; MOTS-c; Sleep; The Regulatory and Practice Framework
ULON-REF-0022,22,Corpas,1992,"Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 1992;75:530-535.",,,,Journal article or scholarly source,,12,Sermorelin
ULON-REF-0023,23,Cruz-Jentoft,2019,"Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16-31. Correction: Age Ageing. 2019;48:601. doi:10.1093/ageing/afy169.",10.1093/ageing/afy169,https://doi.org/10.1093/ageing/afy169,https://doi.org/10.1093/ageing/afy169,Journal article or scholarly source,,,
ULON-REF-0024,24,Dalmasso,2008,"Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008;134:166-178.",,,,Journal article or scholarly source,LL-37 and KPV; Peptides,22,LL-37 and KPV
ULON-REF-0025,25,de Lima Beltrão,2025,"de Lima Beltrão FE, Carvalhal G, de Almeida Beltrão DC, et al. Treatment Preferences in Patients With Hypothyroidism. J Clin Endocrinol Metab. 2025;110(3):887-900. doi:10.1210/clinem/dgae651.",10.1210/clinem/dgae651,https://doi.org/10.1210/clinem/dgae651,https://doi.org/10.1210/clinem/dgae651,Journal article or scholarly source,Hormone Optimization; Thyroid Hormone,30,Thyroid Hormone
ULON-REF-0026,26,United States Congress,1994,"Dietary Supplement Health and Education Act of 1994, Pub L No. 103-417, 108 Stat 4325 (codified at 21 USC §§ 321 et seq.).",,,,Statute,,,
ULON-REF-0027,27,United States Congress,2013,"Drug Quality and Security Act, Pub L No. 113-54 (2013).",,,,Statute,Regulatory and Compounding Policy,3; 42,The Regulatory Landscape — August 2026 Evidence Review; The Regulatory and Practice Framework
ULON-REF-0028,28,Gong,2019,"Gong Q, Zhang P, Wang J, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019;7:452-461. doi:10.1016/S2213-8587(19)30093-2.",10.1016/S2213-8587(19)30093-2,https://doi.org/10.1016/S2213-8587(19)30093-2,https://doi.org/10.1016/S2213-8587(19)30093-2,Journal article or scholarly source,,46,Maintenance — The Long-Term Framework
ULON-REF-0029,29,Eli Lilly and Company,2025,"Eli Lilly and Company. Lilly’s retatrutide reduced body weight by 28.7% in adults living with obesity and knee osteoarthritis in pivotal Phase 3 TRIUMPH-4 study. Press release, December 11, 2025.",,,https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average,Press release or company notice,GLP-1 and GIP Therapies; Retatrutide,21,Retatrutide
ULON-REF-0030,30,Endocrine Society,2026,"Endocrine Society. Testosterone therapy for hypogonadism guideline resources. Clinical practice guideline, current webpage accessed August 13, 2026.",,,https://www.endocrine.org/clinical-practice-guidelines/testosterone-therapy,Guideline or position statement,Hormone Optimization; Testosterone,28,Testosterone
ULON-REF-0031,31,Endocrine Society,2026,"Endocrine Society. Statement on testosterone replacement therapy. July 16, 2026.",,,https://www.endocrine.org/news-and-advocacy/news-room/2026/statement-on-testosterone-replacement-therapy,Journal article or scholarly source,Hormone Optimization; Testosterone,28,Testosterone
ULON-REF-0032,32,Eng,1992,"Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992;267:7402-7405.",,,,Journal article or scholarly source,Peptide Foundations,1; 2,"The Body Speaks in Signals; Not a Steroid, Not a Supplement, Not Snake Oil"
ULON-REF-0033,33,Estruch,2018,"Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med 2018;378:e34.",,,,Journal article or scholarly source,Lifestyle Foundations; Nutrition,36,Nutrition
ULON-REF-0034,34,Falutz,2007,"Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357:2359-2370.",,,,Journal article or scholarly source,,9,Tesamorelin
ULON-REF-0035,35,Falutz,2010,"Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010;95:4291-4304.",,,,Clinical trial or trial report,Growth Hormone Axis; Tesamorelin,9,Tesamorelin
ULON-REF-0036,36,Falutz,2010,"Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr 2010;53:311-322.",,,,Randomized clinical trial,Growth Hormone Axis; Tesamorelin,9,Tesamorelin
ULON-REF-0037,37,Food and Drug Administration,2019,"Food and Drug Administration. FDA approves first oral GLP-1 treatment for type 2 diabetes (Rybelsus). News release, September 20, 2019.",,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf,Government or regulatory source,GLP-1 Therapies; Orforglipron,24,Orforglipron
ULON-REF-0038,38,Food and Drug Administration,2026,"Food and Drug Administration. Bulk drug substances used in compounding under section 503A of the FD&C Act: nomination categories and interim enforcement policy. Current agency webpage, accessed August 13, 2026.",,,https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act,Government or regulatory source,Regulatory and Compounding Policy,3; 42,The Regulatory Landscape — August 2026 Evidence Review; The Regulatory and Practice Framework
ULON-REF-0039,39,Food and Drug Administration,2026,"Food and Drug Administration. Certain bulk drug substances for use in compounding may present significant safety risks. Current agency webpage, accessed August 13, 2026.",,,https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks,Government or regulatory source,Regulatory and Compounding Policy,3; 42,The Regulatory Landscape — August 2026 Evidence Review; The Regulatory and Practice Framework
ULON-REF-0040,40,Food and Drug Administration,2026,"Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Updated through May 31, 2026; accessed August 13, 2026.",,,https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss,Government or regulatory source,Regulatory and Compounding Policy,3; 42,The Regulatory Landscape — August 2026 Evidence Review; The Regulatory and Practice Framework
ULON-REF-0041,41,Food and Drug Administration,2026,"Food and Drug Administration. July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting materials, including FDA introductory and substance-specific briefing documents for BPC-157, emideltide, epitalon, KPV, MOTS-c, Semax, and TB-500. Accessed August 13, 2026.",,,https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026,Government or regulatory source,BPC-157; Epitalon; LL-37 and KPV; MOTS-c; Mitochondrial Health; Peptides; Regulatory and Compounding Policy; TB-500 and Thymosin Beta-4,3; 17; 18; 20; 22; 23; 42,The Regulatory Landscape — August 2026 Evidence Review; BPC-157; TB-500 (Thymosin Beta-4); Epitalon; LL-37 and KPV; MOTS-c; The Regulatory and Practice Framework
ULON-REF-0042,42,Food and Drug Administration,2025,"Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. Drug safety communication, February 28, 2025.",,,https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products,Government or regulatory source,Hormone Optimization; Testosterone,28,Testosterone
ULON-REF-0043,43,Food and Drug Administration,2026,"Food and Drug Administration. FDA approves first oral PCSK9 inhibitor to lower LDL cholesterol in adults with high cholesterol (Lipfendra). News release, 2026.",,,https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol,Government or regulatory source,,,
ULON-REF-0044,44,Food and Drug Administration,2025,"Food and Drug Administration. FDA approves treatment for metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. News release, 2025; ongoing accelerated-approval confirmatory study status accessed August 13, 2026.",,,https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215256Orig1s024ltr.pdf,Government or regulatory source,,,
ULON-REF-0045,45,Food and Drug Administration,2025,"Food and Drug Administration. Drug Trials Snapshot: Forzinity (elamipretide). September 2025; accelerated-approval confirmatory study status accessed August 13, 2026.",,,https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-forzinity,Government or regulatory source,Elamipretide; Mitochondrial Health,10,Elamipretide
ULON-REF-0046,46,Food and Drug Administration,2023,"Food and Drug Administration. Interim category 2 of the 503A Bulks List. Federal Register, September 29, 2023.",,,https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks,Government or regulatory source,Regulatory and Compounding Policy,3; 42,The Regulatory Landscape — August 2026 Evidence Review; The Regulatory and Practice Framework
ULON-REF-0047,47,Food and Drug Administration,2026,"Food and Drug Administration. Removal of certain bulk drug substances from interim category 2 of the 503A Bulks List. Federal Register, April 15, 2026.",,,https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks,Government or regulatory source,Regulatory and Compounding Policy,3; 42,The Regulatory Landscape — August 2026 Evidence Review; The Regulatory and Practice Framework
ULON-REF-0048,48,Frías,2021,"Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385:503-515.",,,,Journal article or scholarly source,GLP-1 Therapies; GLP-1 and GIP Therapies; Semaglutide; Tirzepatide,6; 7,"Semaglutide: More Than a Weight-Loss Drug; Tirzepatide: Two Signals, One Powerful Therapy"
ULON-REF-0049,49,Lindström,2006,"Lindström J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673-1679. doi:10.1016/S0140-6736(06)69701-8.",10.1016/S0140-6736(06)69701-8,https://doi.org/10.1016/S0140-6736(06)69701-8,https://doi.org/10.1016/S0140-6736(06)69701-8,Journal article or scholarly source,,46,Maintenance — The Long-Term Framework
ULON-REF-0050,50,Gelbard,2013,"Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2013;190:199-207.",,,,Randomized clinical trial,Sexual Wellness; Urologic Health,39,Sexual Wellness
ULON-REF-0051,51,Goldstein,1977,"Goldstein AL, Low TLK, McAdoo M, et al. Thymosin α1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci U S A 1977;74:725-729.",,,,Journal article or scholarly source,Immune Health; Thymosin Alpha-1,16; 18,Thymosin Alpha-1; TB-500 (Thymosin Beta-4)
ULON-REF-0052,52,Grönberg,2014,"Grönberg A, Mahlapuu M, Ståhle M, et al. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen 2014;22:613-621.",,,,Randomized clinical trial,LL-37 and KPV; Peptides,22,LL-37 and KPV
ULON-REF-0053,53,Gupta,2022,"Gupta AK, Bamimore MA, Foley KA. Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment of evidence quality. J Dermatolog Treat 2022;33:62-72.",,,,Systematic review,Aesthetic Medicine; Evidence Evaluation; Hair Restoration,4; 38,Reading the Evidence in a Hype-Saturated Field; Hair Restoration
ULON-REF-0054,54,Hannum,2013,"Hannum G, Guinney J, Zhao L, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell 2013;49:359-367.",,,,Journal article or scholarly source,,48,The Future of Comprehensive Practice
ULON-REF-0055,55,Harman,1956,Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956;11:298-300.,,,,Journal article or scholarly source,,,
ULON-REF-0056,56,Harrison,2009,"Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009;460:392-395.",,,,Journal article or scholarly source,Molecular Longevity; Rapamycin and mTOR,26; 48,Rapamycin and the mTOR Pathway; The Future of Comprehensive Practice
ULON-REF-0057,57,Hickson,2019,"Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine 2019;47:446-456.",,,,Journal article or scholarly source,Molecular Longevity; Senolytics,27,Senolytics — Clearing Senescent Cells
ULON-REF-0058,58,HLB Therapeutics,2025,"HLB Therapeutics. European Phase 3 SEER-3 topline results for RGN-259 in neurotrophic keratopathy. Company notice, June 24, 2025; independent coverage published July 1, 2025.",,,https://filecache.investorroom.com/mr5ir_regenerx_ir/215/Letter%20to%20Stockholders%206-24-2025.pdf,Press release or company notice,Peptides; TB-500 and Thymosin Beta-4,18,TB-500 (Thymosin Beta-4)
ULON-REF-0059,59,Hohl,2025,"Hohl A, Chavez MP, Pasqualotto E, et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Arch Endocrinol Metab. 2025;69(5):e250093. doi:10.20945/2359-4292-2025-0093.",10.20945/2359-4292-2025-0093,https://doi.org/10.20945/2359-4292-2025-0093,https://doi.org/10.20945/2359-4292-2025-0093,Meta-analysis,Hormone Optimization; Testosterone,28,Testosterone
ULON-REF-0060,60,Hohl,2025,"Hohl A, Marques P, Ronsoni MF, et al. Selective estrogen receptor modulators (SERMs) for male hypogonadism: a meta-analysis of randomized controlled trials. Arch Endocrinol Metab 2025; published online ahead of print.",,,,Meta-analysis,Hormone Optimization; Testosterone,28,Testosterone
ULON-REF-0061,61,Horvath,2018,"Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet 2018;19:371-384.",,,,Journal article or scholarly source,Biological Aging; Lifespan Framework,47; 48,The Lifespan Framework — Adaptation Across Demographics; The Future of Comprehensive Practice
ULON-REF-0062,62,Horvath,2013,Horvath S. DNA methylation age of human tissues and cell types. Genome Biol 2013;14:R115.,,,,Journal article or scholarly source,Biological Aging; Lifespan Framework,47; 48,The Lifespan Framework — Adaptation Across Demographics; The Future of Comprehensive Practice
ULON-REF-0063,63,Hróbjartsson,2012,"Hróbjartsson A, Thomsen ASS, Emanuelsson F, et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ 2012;344:e1119.",,,,Systematic review,Evidence Evaluation,4,Reading the Evidence in a Hype-Saturated Field
ULON-REF-0064,64,Hughes,2013,"Hughes MCB, Williams GM, Baker P, Green AC. Sunscreen and prevention of skin aging: a randomized trial. Ann Intern Med 2013;158:781-790.",,,,Randomized clinical trial,Skin and Aesthetic Medicine,40,Skin and Aesthetic Interventions
ULON-REF-0065,65,Imperiale,2014,"Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370:1287-1297. (Cologuard pivotal trial.)",,,,Journal article or scholarly source,Early Detection and Intervention,44,Early Intervention and the Minimally Invasive Framework
ULON-REF-0066,66,Ionescu,2006,"Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91:4792-4797.",,,,Journal article or scholarly source,CJC-1295; Growth Hormone; Growth Hormone Axis; Hormone Optimization,14; 29,CJC-1295; Growth Hormone
ULON-REF-0067,67,Jastreboff,2022,"Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205-216.",,,,Journal article or scholarly source,GLP-1 and GIP Therapies; Tirzepatide,7; 21,"Tirzepatide: Two Signals, One Powerful Therapy; Retatrutide"
ULON-REF-0068,68,Jastreboff,2023,"Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. N Engl J Med 2023;389:514-526.",,,,Clinical trial or trial report,GLP-1 and GIP Therapies; Retatrutide,21,Retatrutide
ULON-REF-0069,69,Kaeberlein,2023,"Kaeberlein TL, Green AS, Haddad G, et al. Evaluation of off-label rapamycin use to promote healthspan in 333 adults. GeroScience 2023;45:2757-2768.",,,,Journal article or scholarly source,Molecular Longevity; Rapamycin and mTOR; Regulatory and Compounding Policy,3; 26; 42,The Regulatory Landscape — August 2026 Evidence Review; Rapamycin and the mTOR Pathway; The Regulatory and Practice Framework
ULON-REF-0070,70,Kawai,2020,"Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci U S A 2020;117:29959-29967.",,,,Journal article or scholarly source,GLP-1 Therapies; Orforglipron,24,Orforglipron
ULON-REF-0071,71,Khavinson,2003,"Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 2003;135:590-592.",,,,Journal article or scholarly source,Epitalon; Peptides,3; 19; 20,The Regulatory Landscape — August 2026 Evidence Review; GHK-Cu; Epitalon
ULON-REF-0072,72,Khavinson,2003,"Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuroendocrinology Letters 2003;24:233-240.",,,,Journal article or scholarly source,,3; 19; 20,The Regulatory Landscape — August 2026 Evidence Review; GHK-Cu; Epitalon
ULON-REF-0073,73,Khorram,1997,"Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997;82:1472-1479.",,,,Journal article or scholarly source,,12,Sermorelin
ULON-REF-0074,74,Kingsberg,2019,"Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol 2019;134:899-908. (RECONNECT-1 and RECONNECT-2.)",,,,Randomized clinical trial,Bremelanotide; Sexual Wellness; Urologic Health,11; 39,PT-141 (Bremelanotide); Sexual Wellness
ULON-REF-0075,75,Klier,2025,"Klier S, Dananberg J, Masaki L, et al. Safety and efficacy of senolytic UBX1325 in diabetic macular edema. NEJM Evidence 2025;4:EVIDoa2400009.",,,,Journal article or scholarly source,Molecular Longevity; Senolytics,27,Senolytics — Clearing Senescent Cells
ULON-REF-0076,76,Kligman,1986,"Kligman AM, Grove GL, Hirose R, Leyden JJ. Topical tretinoin for photoaged skin. J Am Acad Dermatol 1986;15:836-859.",,,,Journal article or scholarly source,Skin and Aesthetic Medicine,40,Skin and Aesthetic Interventions
ULON-REF-0077,77,Kokkinos,2022,"Kokkinos P, Faselis C, Samuel IBH, et al. Cardiorespiratory fitness and mortality risk across the spectra of age, race, and sex. J Am Coll Cardiol 2022;80:598-609.",,,,Journal article or scholarly source,Exercise; Lifestyle Foundations,33; 34,The Integration Framework; Exercise
ULON-REF-0078,78,Kosiborod,2023,"Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069-1084.",,,,Journal article or scholarly source,GLP-1 Therapies; Semaglutide,6,Semaglutide: More Than a Weight-Loss Drug
ULON-REF-0079,79,Lee,2015,"Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015;21:443-454.",,,,Journal article or scholarly source,MOTS-c; Mitochondrial Health,23,MOTS-c
ULON-REF-0080,80,Lehallier,2019,"Lehallier B, Gate D, Schaum N, et al. Undulating changes in human plasma proteome profiles across the lifespan. Nat Med 2019;25:1843-1850.",,,,Journal article or scholarly source,Biological Aging; Lifespan Framework,47; 48,The Lifespan Framework — Adaptation Across Demographics; The Future of Comprehensive Practice
ULON-REF-0081,81,Leong,2015,"Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet 2015;386:266-273.",,,,Journal article or scholarly source,Exercise; Lifestyle Foundations,34; 43; 45; 46,Exercise; Integrated Practice; The First 90 Days; Maintenance — The Long-Term Framework
ULON-REF-0082,82,Levine,2018,"Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY) 2018;10:573-591. (PhenoAge.)",,,,Journal article or scholarly source,Biological Aging; Lifespan Framework,47; 48,The Lifespan Framework — Adaptation Across Demographics; The Future of Comprehensive Practice
ULON-REF-0083,83,Lincoff,2023,"Lincoff AM, Bhasin S, Flevaris P, et al; TRAVERSE Study Investigators. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med 2023;389:107-117.",,,,Journal article or scholarly source,Hormone Optimization; Testosterone,28,Testosterone
ULON-REF-0084,84,Lincoff,2023,"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221-2232.",,,,Journal article or scholarly source,GLP-1 Therapies; Semaglutide,6; 28,Semaglutide: More Than a Weight-Loss Drug; Testosterone
ULON-REF-0085,85,Liu,2007,"Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007;146:104-115.",,,,Systematic review,Growth Hormone; Hormone Optimization,29,Growth Hormone
ULON-REF-0086,86,Livingston,2020,"Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 2020;396:413-446.",,,,Journal article or scholarly source,Cognitive Health; Mental Work,37; 47,Mental Work; The Lifespan Framework — Adaptation Across Demographics
ULON-REF-0087,87,Low,1981,"Low TLK, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin β4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci U S A 1981;78:1162-1166.",,,,Journal article or scholarly source,Peptides; TB-500 and Thymosin Beta-4,18,TB-500 (Thymosin Beta-4)
ULON-REF-0088,88,Lu,2019,"Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY) 2019;11:303-327.",,,,Journal article or scholarly source,Biological Aging; Lifespan Framework,47,The Lifespan Framework — Adaptation Across Demographics
ULON-REF-0089,89,Lucente,2024,"Lucente V, MacDiarmid S, Khera M, et al. Two-year results from a prospective, multicenter, single-arm pivotal study of an implantable tibial neuromodulation system for the treatment of urinary urgency incontinence. Urology 2024;186:80-87.",,,,Journal article or scholarly source,Bladder and Pelvic Floor Health; Urologic Health,41,"Bladder, Pelvic Floor, and Continence Rehabilitation"
ULON-REF-0090,90,Lundh,2017,"Lundh A, Lexchin J, Mintzes B, et al. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2017;2:MR000033.",,,,Journal article or scholarly source,Evidence Evaluation,4,Reading the Evidence in a Hype-Saturated Field
ULON-REF-0091,91,López-Otín,2023,"López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell 2023;186:243-278.",,,,Journal article or scholarly source,Biology of Aging; Future of Longevity Medicine,5; 48,The Biology of Aging; The Future of Comprehensive Practice
ULON-REF-0092,92,López-Otín,2013,"López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013;153:1194-1217.",,,,Journal article or scholarly source,Biology of Aging; Future of Longevity Medicine,5; 48,The Biology of Aging; The Future of Comprehensive Practice
ULON-REF-0093,93,Malhotra,2024,"Malhotra A, Grunstein RR, Fietze I, et al; SURMOUNT-OSA Investigators. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med 2024;391:1193-1205.",,,,Journal article or scholarly source,GLP-1 and GIP Therapies; Lifestyle Foundations; Sleep; Tirzepatide,7; 35,"Tirzepatide: Two Signals, One Powerful Therapy; Sleep"
ULON-REF-0094,94,Mandsager,2018,"Mandsager K, Harb S, Cremer P, et al. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Netw Open 2018;1:e183605.",,,,Journal article or scholarly source,Exercise; Lifestyle Foundations,33; 34; 43,The Integration Framework; Exercise; Integrated Practice
ULON-REF-0095,95,Mannick,2014,"Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med 2014;6:268ra179.",,,,Journal article or scholarly source,Molecular Longevity; Rapamycin and mTOR,26; 48,Rapamycin and the mTOR Pathway; The Future of Comprehensive Practice
ULON-REF-0096,96,Mannick,2018,"Mannick JB, Morris M, Hockey HU, et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med 2018;10:eaaq1564.",,,,Journal article or scholarly source,Molecular Longevity; Rapamycin and mTOR,26; 48,Rapamycin and the mTOR Pathway; The Future of Comprehensive Practice
ULON-REF-0097,97,Manson,2013,"Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353-1368.",,,,Randomized clinical trial,Female Reproductive Hormones; Hormone Optimization,31,Female Reproductive Hormones — Perimenopause and Menopause
ULON-REF-0098,98,Marso,2016,"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-1844.",,,,Journal article or scholarly source,GLP-1 Therapies; Semaglutide,6,Semaglutide: More Than a Weight-Loss Drug
ULON-REF-0099,99,Marso,2016,"Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-322.",,,,Journal article or scholarly source,GLP-1 Therapies; Liraglutide,8,Liraglutide
ULON-REF-0100,100,Martens,2018,"Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD⁺ in healthy middle-aged and older adults. Nat Commun 2018;9:1286.",,,,Journal article or scholarly source,Molecular Longevity; NAD+,25,NAD⁺ and Its Precursors
ULON-REF-0101,101,McDermott,2024,"McDermott MM, Martens CR, Domanchuk KJ, et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nat Commun 2024;15:5046.",,,,Randomized clinical trial,Molecular Longevity; NAD+,25,NAD⁺ and Its Precursors
ULON-REF-0102,102,McEvoy,2016,"McEvoy RD, Antic NA, Heeley E, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med 2016;375:919-931.",,,,Journal article or scholarly source,Lifestyle Foundations; Sleep,35,Sleep
ULON-REF-0103,103,Merrifield,1963,"Merrifield RB. Solid phase peptide synthesis I: The synthesis of a tetrapeptide. J Am Chem Soc 1963;85:2149-2154. (Nobel Prize in Chemistry, 1984.)",,,,Journal article or scholarly source,Peptide Foundations,1; 2,"The Body Speaks in Signals; Not a Steroid, Not a Supplement, Not Snake Oil"
ULON-REF-0104,104,MESA Investigators,,MESA Investigators — see Budoff MJ et al. (above) for the contemporary CAC-mortality framework citation.,,,,Cross-reference,,,
ULON-REF-0105,105,Moel,2025,"Moel M, Harinath G, Lee V, et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY) 2025;17:908-936.",,,,Journal article or scholarly source,Molecular Longevity; Rapamycin and mTOR,26; 48,Rapamycin and the mTOR Pathway; The Future of Comprehensive Practice
ULON-REF-0106,106,Nadon,2017,"Nadon NL, Strong R, Miller RA, Harrison DE. NIA Interventions Testing Program: investigating putative aging intervention agents in a genetically heterogeneous mouse model. eBioMedicine 2017;21:3-4.",,,,Journal article or scholarly source,,,
ULON-REF-0107,107,Nair,2006,"Nair KS, Rizza RA, O’Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006;355:1647-1659.",,,,Journal article or scholarly source,DHEA and Adrenal Steroids; Hormone Optimization; Testosterone,28; 32,Testosterone; DHEA and Adrenal Steroids
ULON-REF-0108,108,Nass,2008,"Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008;149:601-611.",,,,Randomized clinical trial,,15,MK-677 (Ibutamoren)
ULON-REF-0109,109,Ngandu,2015,"Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015;385:2255-2263.",,,,Randomized clinical trial,Cognitive Health; Lifestyle Foundations; Mental Work; Nutrition,36; 37; 43,Nutrition; Mental Work; Integrated Practice
ULON-REF-0110,110,Nicholls,2025,"Nicholls SJ, Bhatt DL, Buse JB, et al; SURPASS-CVOT Investigators. Cardiovascular efficacy and safety of tirzepatide in patients with type 2 diabetes and atherosclerotic cardiovascular disease. N Engl J Med 2025;393:2347-2358.",,,,Journal article or scholarly source,GLP-1 and GIP Therapies; Tirzepatide,7,"Tirzepatide: Two Signals, One Powerful Therapy"
ULON-REF-0111,111,Nishihara,2013,"Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369:1095-1105.",,,,Journal article or scholarly source,,44; 46,Early Intervention and the Minimally Invasive Framework; Maintenance — The Long-Term Framework
ULON-REF-0112,112,Nobel Assembly at Karolinska Institutet,2009,"Nobel Assembly at Karolinska Institutet. The Nobel Prize in Physiology or Medicine 2009: Elizabeth H. Blackburn, Carol W. Greider and Jack W. Szostak. October 5, 2009.",,,https://www.nobelprize.org/prizes/medicine/2009/press-release/,Institutional historical source,,,
ULON-REF-0113,113,Novo Nordisk,2025,"Novo Nordisk. Evoke and evoke+ trials of oral semaglutide in early Alzheimer’s disease did not meet primary endpoint. Press release, November 24, 2025.",,,https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916462,Press release or company notice,Cognitive Health; GLP-1 Therapies; Mental Work; Semaglutide,6; 37,Semaglutide: More Than a Weight-Loss Drug; Mental Work
ULON-REF-0114,114,Ocampo,2016,"Ocampo A, Reddy P, Martinez-Redondo P, et al. In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell 2016;167:1719-1733.e12.",,,,Journal article or scholarly source,Biology of Aging; Future of Longevity Medicine,5; 48,The Biology of Aging; The Future of Comprehensive Practice
ULON-REF-0115,115,Outterson,2012,Outterson K. Regulating compounding pharmacies after NECC. N Engl J Med 2012;367:1969-1972.,,,,Journal article or scholarly source,Regulatory and Compounding Policy,3; 42,The Regulatory Landscape — August 2026 Evidence Review; The Regulatory and Practice Framework
ULON-REF-0116,116,Appel,2003,"Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289:2083-2093. doi:10.1001/jama.289.16.2083.",10.1001/jama.289.16.2083,https://doi.org/10.1001/jama.289.16.2083,https://doi.org/10.1001/jama.289.16.2083,Journal article or scholarly source,,,
ULON-REF-0117,117,Mack,2019,"Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705. doi:10.1056/NEJMoa1814052.",10.1056/NEJMoa1814052,https://doi.org/10.1056/NEJMoa1814052,https://doi.org/10.1056/NEJMoa1814052,Journal article or scholarly source,Early Detection and Intervention,44,Early Intervention and the Minimally Invasive Framework
ULON-REF-0118,118,Patchett,1995,"Patchett AA, Nargund RP, Tata JR, et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A 1995;92:7001-7005.",,,,Journal article or scholarly source,Growth Hormone Axis; MK-677,15,MK-677 (Ibutamoren)
ULON-REF-0119,119,Paulescu,1921,Paulescu NC. Recherche sur le rôle du pancréas dans l’assimilation nutritive. Arch Int Physiol 1921;17:85-103.,,,,Journal article or scholarly source,,,
ULON-REF-0120,120,Penha,2024,"Penha MÁ, Miot HA, Kasprzak M, et al. Oral minoxidil 5 mg daily versus topical minoxidil 5% twice daily for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatol 2024;160:600-605.",,,,Randomized clinical trial,Aesthetic Medicine; Hair Restoration,38,Hair Restoration
ULON-REF-0121,121,Peppard,2013,"Peppard PE, Young T, Barnet JH, et al. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 2013;177:1006-1014.",,,,Journal article or scholarly source,Lifestyle Foundations; Sleep,35,Sleep
ULON-REF-0122,122,Perkovic,2024,"Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024;391:109-121.",,,,Journal article or scholarly source,GLP-1 Therapies; Semaglutide,6,Semaglutide: More Than a Weight-Loss Drug
ULON-REF-0123,123,Perls,2005,"Perls TT, Reisman NR, Olshansky SJ. Provision or distribution of growth hormone for “antiaging”: clinical and legal issues. JAMA 2005;294:2086-2090.",,,,Journal article or scholarly source,Growth Hormone; Hormone Optimization,29,Growth Hormone
ULON-REF-0124,124,Peters,2010,"Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 2010;183:1438-1443.",,,,Randomized clinical trial,Bladder and Pelvic Floor Health; Urologic Health,41,"Bladder, Pelvic Floor, and Continence Rehabilitation"
ULON-REF-0125,125,Pi-Sunyer,2015,"Pi-Sunyer X, Astrup A, Fujioka K, et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22.",,,,Randomized clinical trial,GLP-1 Therapies; Liraglutide,8,Liraglutide
ULON-REF-0126,126,Pickart,1980,"Pickart L, Thaler MM. Growth-modulating tripeptide (glycyl-histidyl-lysine): association with copper and iron in plasma, and stimulation of adhesiveness and growth of hepatoma cells in culture by tripeptide-metal ion complexes. J Cell Physiol 1980;102:129-139.",,,,Journal article or scholarly source,GHK-Cu; Skin and Aesthetic Medicine,19; 40,GHK-Cu; Skin and Aesthetic Interventions
ULON-REF-0127,127,Pickart,2015,"Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015;2015:648108.",,,,Journal article or scholarly source,GHK-Cu; Skin and Aesthetic Medicine,19; 40,GHK-Cu; Skin and Aesthetic Interventions
ULON-REF-0128,128,Radley,2006,"Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166:1021-1026.",,,,Journal article or scholarly source,Regulatory and Compounding Policy,3; 42,The Regulatory Landscape — August 2026 Evidence Review; The Regulatory and Practice Framework
ULON-REF-0129,129,Raun,1998,"Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139:552-561.",,,,Journal article or scholarly source,Growth Hormone Axis; Ipamorelin,13,Ipamorelin
ULON-REF-0130,130,Reid Thompson,2021,"Reid Thompson W, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Genet Med 2021;23:471-478. (TAZPOWER trial.)",,,,Randomized clinical trial,Elamipretide; Mitochondrial Health,10,Elamipretide
ULON-REF-0131,131,Reynolds,2021,"Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun 2021;12:470.",,,,Journal article or scholarly source,Exercise; Lifestyle Foundations; MOTS-c; Mitochondrial Health,23; 34,MOTS-c; Exercise
ULON-REF-0132,132,Romani,2004,"Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 2004;103:4232-4239.",,,,Journal article or scholarly source,Immune Health; Thymosin Alpha-1,16,Thymosin Alpha-1
ULON-REF-0133,133,Safarinejad,2008,"Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol 2008;179:1066-1071.",,,,Randomized clinical trial,Bremelanotide; Sexual Wellness; Urologic Health,11; 39,PT-141 (Bremelanotide); Sexual Wellness
ULON-REF-0134,134,Sanyal,2025,"Sanyal AJ, Newsome PN, Kliers I, et al; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 2025;392:2089-2099.",,,,Clinical trial or trial report,GLP-1 Therapies; Semaglutide,6,Semaglutide: More Than a Weight-Loss Drug
ULON-REF-0135,135,Savin,2024,"Savin MJ, Wang H, Pei H, et al. Association of a pace of aging epigenetic clock with rate of cognitive decline in the Framingham Heart Study Offspring Cohort. Alzheimers Dement (Amst). 2024;16(4):e70038. doi:10.1002/dad2.70038.",10.1002/dad2.70038,https://doi.org/10.1002/dad2.70038,https://doi.org/10.1002/dad2.70038,Journal article or scholarly source,Biological Aging; Cognitive Health; Lifespan Framework; Mental Work,37; 47; 48,Mental Work; The Lifespan Framework — Adaptation Across Demographics; The Future of Comprehensive Practice
ULON-REF-0136,136,Schmauck-Medina,2022,"Schmauck-Medina T, Molière A, Lautrup S, et al. New hallmarks of ageing: a 2022 Copenhagen ageing meeting summary. Aging (Albany NY) 2022;14:6829-6839.",,,,Journal article or scholarly source,Biology of Aging; Future of Longevity Medicine,5; 48,The Biology of Aging; The Future of Comprehensive Practice
ULON-REF-0137,137,Schweiger,2025,"Schweiger A, Diniz B, Nicol G, et al. Protocol for a pilot clinical trial of the senolytic drug combination dasatinib plus quercetin to mitigate age-related health and cognitive decline in mental disorders. F1000Res. 2025;13:1072. doi:10.12688/f1000research.151963.2.",10.12688/f1000research.151963.2,https://doi.org/10.12688/f1000research.151963.2,https://doi.org/10.12688/f1000research.151963.2,Journal article or scholarly source,Cognitive Health; Mental Work; Molecular Longevity; Senolytics,27; 37; 48,Senolytics — Clearing Senescent Cells; Mental Work; The Future of Comprehensive Practice
ULON-REF-0138,138,Sikiric,1993,"Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris 1993;87:313-327.",,,,Journal article or scholarly source,BPC-157; Peptides,17,BPC-157
ULON-REF-0139,139,Simon,2019,"Simon JA, Kingsberg SA, Goldstein I, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol 2019;134:909-917.",,,,Journal article or scholarly source,Bremelanotide; Sexual Wellness; Urologic Health,11; 39,PT-141 (Bremelanotide); Sexual Wellness
ULON-REF-0140,140,Sosne,2023,"Sosne G, Kleinman HK, Springs C, et al. 0.1% RGN-259 (Thymosin β4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked Phase III clinical trial. Int J Mol Sci 2023;24:554.",,,,Randomized clinical trial,Peptides; TB-500 and Thymosin Beta-4,18,TB-500 (Thymosin Beta-4)
ULON-REF-0141,141,Stanley,2019,"Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019;6:e821-e830.",,,,Randomized clinical trial,Growth Hormone Axis; Tesamorelin,9,Tesamorelin
ULON-REF-0142,142,Stealth BioTherapeutics Inc,2025,"Stealth BioTherapeutics Inc. Stealth BioTherapeutics announces FDA accelerated approval of Forzinity (elamipretide HCl), the first therapy for progressive and life-limiting ultra-rare genetic disease Barth syndrome. Press release, September 19, 2025.",,,https://stealthbt.com/stealth-biotherapeutics-announces-fda-accelerated-approval-of-forzinity-elamipretide-hcl-the-first-therapy-for-progressive-and-life-limiting-ultra-rare-genetic-disease-barth-syndrome/,Press release or company notice,Elamipretide; Mitochondrial Health,10,Elamipretide
ULON-REF-0143,143,Stott,2017,"Stott DJ, Rodondi N, Kearney PM, et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med 2017;376:2534-2544. (TRUST trial.)",,,,Journal article or scholarly source,Hormone Optimization; Thyroid Hormone,30; 47,Thyroid Hormone; The Lifespan Framework — Adaptation Across Demographics
ULON-REF-0144,144,Talpos,2026,"Talpos S. How a Croatian Lab Spawned a Buzzy Peptide Now Popular With MAHA. Undark. February 3, 2026. Co-published by STAT.",,,,Journal article or scholarly source,,17,BPC-157
ULON-REF-0145,145,Teichman,2006,"Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91:799-805.",,,,Journal article or scholarly source,CJC-1295; Growth Hormone; Growth Hormone Axis; Hormone Optimization,14; 29,CJC-1295; Growth Hormone
ULON-REF-0146,146,North American Menopause Society Advisory Panel,2022,The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. Menopause 2022;29:767-794.,,,https://menopause.org/professional-resources/position-statements,Guideline or position statement,Female Reproductive Hormones; Hormone Optimization,31,Female Reproductive Hormones — Perimenopause and Menopause
ULON-REF-0147,147,U.S. Department of Justice,2020,"U.S. Department of Justice. Nicholasville compounding pharmacy and its owner plead guilty to unlawful distribution of prescription drugs. Press release, October 5, 2020. (Tailor Made Compounding LLC.)",,,https://www.justice.gov/usao-edky/pr/nicholasville-compounding-pharmacy-and-its-owner-plead-guilty-unlawful-distribution,Government or regulatory source,Regulatory and Compounding Policy,3; 42,The Regulatory Landscape — August 2026 Evidence Review; The Regulatory and Practice Framework
ULON-REF-0148,148,McGuire,2025,"McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18:611-619. doi:10.1007/s12178-025-09990-7.",10.1007/s12178-025-09990-7,https://doi.org/10.1007/s12178-025-09990-7,https://doi.org/10.1007/s12178-025-09990-7,Review article,BPC-157; Peptides,17,BPC-157
ULON-REF-0149,149,Vandamme,2012,"Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol 2012;280:22-35.",,,,Journal article or scholarly source,LL-37 and KPV; Peptides,22,LL-37 and KPV
ULON-REF-0150,150,Vittone,1997,"Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism 1997;46:89-96.",,,,Journal article or scholarly source,Growth Hormone; Hormone Optimization,12; 29,Sermorelin; Growth Hormone
ULON-REF-0151,151,Wang,2022,"Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther 2022;7:48.",,,,Journal article or scholarly source,Peptide Foundations,1; 2; 46,"The Body Speaks in Signals; Not a Steroid, Not a Supplement, Not Snake Oil; Maintenance — The Long-Term Framework"
ULON-REF-0152,152,Wharton,2023,"Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389:877-888. doi:10.1056/NEJMoa2302392.",10.1056/NEJMoa2302392,https://doi.org/10.1056/NEJMoa2302392,https://doi.org/10.1056/NEJMoa2302392,Journal article or scholarly source,GLP-1 Therapies; Orforglipron,24,Orforglipron
ULON-REF-0153,153,Wilding,2021,"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989-1002.",,,,Journal article or scholarly source,GLP-1 Therapies; Semaglutide,6,Semaglutide: More Than a Weight-Loss Drug
ULON-REF-0154,154,Xu,2018,"Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med 2018;24:1246-1256.",,,,Journal article or scholarly source,Exercise; Lifestyle Foundations; Molecular Longevity; Senolytics,27; 34,Senolytics — Clearing Senescent Cells; Exercise
ULON-REF-0155,155,Zauber,2012,"Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366:687-696. doi:10.1056/NEJMoa1100370.",10.1056/NEJMoa1100370,https://doi.org/10.1056/NEJMoa1100370,https://doi.org/10.1056/NEJMoa1100370,Journal article or scholarly source,Early Detection and Intervention,44,Early Intervention and the Minimally Invasive Framework
ULON-REF-0156,156,Zeevi,2015,"Zeevi D, Korem T, Zmora N, et al. Personalized nutrition by prediction of glycemic responses. Cell 2015;163:1079-1094.",,,,Journal article or scholarly source,Lifestyle Foundations; Nutrition,36; 48,Nutrition; The Future of Comprehensive Practice
ULON-REF-0157,157,Zhang,2009,"Zhang YY, Chen EQ, Yang J, et al. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol J 2009;6:63.",,,,Meta-analysis,Immune Health; Thymosin Alpha-1,16; 46,Thymosin Alpha-1; Maintenance — The Long-Term Framework
ULON-REF-0158,158,Zhu,2015,"Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 2015;14:644-658.",,,,Journal article or scholarly source,Molecular Longevity; Senolytics,27,Senolytics — Clearing Senescent Cells